Aslan Pharmaceuticals (Aslan)

Oncology Corporate Profile

HQ Location

10A Bukit Pasoh Road
Singapore, 89824

Company Description

ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. The Company's proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN's most advanced compounds are in phase 2: ASLAN001, a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
varlitinibc-Met kinase inhibitorCholangiocarcinomaIII
varlitinibc-Met kinase inhibitorBreast cancerII
varlitinib (+ chemotherapy)c-Met kinase inhibitorBreast cancerII
ASLAN002c-Met kinase inhibitorBreast cancerIIBristol-Myers Squibb
varlitinibc-Met kinase inhibitorColorectal cancerII
ASLAN002c-Met kinase inhibitorGastric cancerIIBristol-Myers Squibb
ASLAN003DHODH inhibitorVarious cancer typesIAlmirall
ASLAN005DHODH inhibitorVarious cancer typesPreclinical
ASLAN004DHODH inhibitorVarious cancer typesPreclinicalCSL Limited

View additional information on product candidates here »


Recent News Headlines

There are no news items to display